2.21% -0.0211

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY) 最新ニュース

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY) 最新ニュース

Oncolytics Biotech Engages Investors at Key Conferences - TipRanks

Oncolytics Biotech Inc - Baystreet.ca

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - IT News Online

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - Quantisnow

Oncolytic Virus Therapy Market to See Booming Growth 2024-2031 | - openPR

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - Barchart

Oncolytics Biotech Inc. Forecasted to Earn FY2024 Earnings of ($0.29) Per Share (NASDAQ:ONCY) - MarketBeat

HC Wainwright Weighs in on Oncolytics Biotech Inc.'s FY2024 Earnings (TSE:ONC) - MarketBeat

HC Wainwright Analysts Decrease Earnings Estimates for Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World

Oncolytics Biotech (NASDAQ:ONCY) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World

Thinking about buying stock in Oncolytics Biotech, Nikola Corp, Joby Aviation, Ideanomics, or Better Therapeutics? - GuruFocus.com

Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus.com

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer - Longview News-Journal

Oncolytics Biotech’s Pelareorep Shows Promise in Metastatic Breast Cancer Treatment - Vancity Buzz

Stock Surge: Oncolytics Biotech, Inc. (ONCY) Closes at 0.91, Marking a -4.06 Increase/Decrease - The Dwinnex

Extending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast Cancer - Nasdaq

Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes - Baystreet.ca

Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates - Barchart

Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates - Quantisnow

Advancements In Cancer Therapeutics: What To Expect From The Upcoming 2024 Oncology Conference - MENAFN.COM

Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected To Reach $7.4 Billion By 2032 - MENAFN.COM

Virtu Financial LLC Acquires New Stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World

Oncolytic Virus Therapy Market Expected to Expand at a Steady - openPR

ONCY:UN - BNN Bloomberg

Oncolytics Biotech Announces Equity Distribution Deal - TipRanks

Earnings call: Oncolytics Biotech outlines progress in cancer trials By Investing.com - Investing.com Australia

Earnings call: Oncolytics Biotech outlines progress in cancer trials By Investing.com - Investing.com UK

Oncolytics Biotech Inc (ONCY) Q2 2024 Earnings Call Transcript H - GuruFocus.com

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - The Malaysian Reserve

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - StreetInsider.com

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - BioSpace

Oncolytics Biotech (TSE:ONC) Stock Passes Above Two Hundred Day Moving Average of $1.47 - Defense World

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference - Financial Times

Oncolytics Biotech (TSE:ONC) Share Price Crosses Above Two Hundred Day Moving Average of $1.47 - MarketBeat

Q2 2024 Oncolytics Biotech Inc Earnings Call Transcript - GuruFocus.com

Earnings call: Oncolytics Biotech outlines progress in cancer trials By Investing.com - Investing.com Canada

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript - Seeking Alpha

Oncolytics Biotech’s Financials Show Asset Decline - TipRanks

Oncolytics Biotech Advances Cancer Trials with Solid Funding - TipRanks

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights - PR Newswire

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference - Kilgore News Herald

Pancreatic Cancer Poised to Become Second Leading Cause of Cancer Death; New Treatment Shows Promise - Vancity Buzz

Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment - Nasdaq

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - Kilgore News Herald

Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment - News Channel Nebraska

Oncolytics Biotech (ONCY) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oncolytics Biotech (ONC) Set to Announce Earnings on Thursday - MarketBeat

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation - Yahoo Finance

Oncolytics Biotech Inc. - Baystreet.ca

Stocks In Play: Oncolytics Biotech Inc. - Barchart

Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational… - Informazione.it

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights - StockTitan

Oncolytics Biotech (NASDAQ:ONCY) Shares Down 1% - MarketBeat

Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 1% - Defense World

Stocks in play: Oncolytics Biotech Inc. - Yahoo Canada Sports

Oncolytics Biotech (TSE:ONC) Stock Price Passes Above 200 Day Moving Average of $1.49 - Defense World

Oncolytics Biotech (TSE:ONC) Stock Crosses Above Two Hundred Day Moving Average of $1.49 - MarketBeat

Oncolytic Virus Immunotherapy Market Opportunities, Growth Analysis And Forecast 2024-2032 - The NRI News

Reviewing Oncolytics Biotech (NASDAQ:ONCY) and Johnson & Johnson (NYSE:JNJ) - American Banking and Market News

Johnson & Johnson (NYSE:JNJ) versus Oncolytics Biotech (NASDAQ:ONCY) Head to Head Analysis - Defense World

ONC:CT: Stock Price, Quote & News - BNN Bloomberg

Oncolytics Biotech (TSE:ONC) Share Price Passes Below Two Hundred Day Moving Average of $1.50 - Defense World

Oncolytics Biotech (TSE:ONC) Share Price Passes Below Two Hundred Day Moving Average of $1.50 - MarketBeat

ONCYに似た銘柄